Recent

% | $
Quotes you view appear here for quick access.

SPDR Dow Jones Industrial Average ETF Message Board

careful_investor_wins 1876 posts  |  Last Activity: 12 hours ago Member since: Apr 8, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • careful_investor_wins by careful_investor_wins Apr 28, 2016 2:30 PM Flag

    This company is so scarily heavy in billions of dollars of debts and unpaid liabilities and not able to be profitable even in this better economy and low interest rate environment. This company will be surely heading for bankruptcy if the economy turns down or the interest rate goes up. This stock should be trading at pennies. The book value of this company is NEGATIVE $5 BILLION DOLLARS (NEGATIVE $63 PER SHARE). No one in his or her right mind would buy this.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins Apr 29, 2016 9:51 AM Flag

    LOL. Most of the bankrupted stocks were heavily owned by institutions. Enron, MCI, Kodak, GM, etc. They were all heavily owned by institutions before bankruptcy. LOL. It meant nothing. Most institutions underperform the market.

    Sentiment: Strong Sell

  • Reply to

    Lets Review

    by aeishh Apr 28, 2016 10:50 AM
    careful_investor_wins careful_investor_wins Apr 29, 2016 10:17 AM Flag

    I simply do not see the connection between a dog and this horrible financial situation money losing company stock. That was a very silly mumbling.

    Sentiment: Strong Sell

  • Reply to

    Lets Review

    by aeishh Apr 28, 2016 10:50 AM
    careful_investor_wins careful_investor_wins Apr 29, 2016 1:49 PM Flag

    What recovery were you talking about? The sales were down 17% year-over-year and still losing money EVERY quarter. The cash in hand is down to only 63% of last year same time while the short-term notes (debts) payable is up 34% to a scary $1.49 billion dollars now. It is getting worse, not better. This company is a scary bankruptcy candidate.

    Sentiment: Strong Sell

  • Reply to

    Lets Review

    by aeishh Apr 28, 2016 10:50 AM
    careful_investor_wins careful_investor_wins Apr 30, 2016 1:39 PM Flag

    Don't confuse market strength as stock strength. When a strong market lifts a bad stock, it is time for you to sell to get out, not time to be complacent because the market will not be up every day. This money losing bankruptcy candidate stock will hit new lows when the market corrects back down.

    Sentiment: Strong Sell

  • Reply to

    Lets Review

    by aeishh Apr 28, 2016 10:50 AM
    careful_investor_wins careful_investor_wins Apr 30, 2016 1:58 PM Flag

    LOL. The only thing this company can resemble Rome is the collapse of Rome. LOL. They have fewer losses because they also have fewer sales. This company is running a hopeless money losing business. They more they sell, the more they lose. If they close the company, they would not lose anything. LOL. That is the ultimate restructure and lean out. LOL. The biggest problem is the scary $5 billion dollars of debts. The interest payment pretty much guarantees this company will keep losing money. And guess what? The interest rates are probably going to go up even higher. It is scary hopeless here.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins Apr 30, 2016 2:09 PM Flag

    Did you forget somebody also bought at $70, $60, $40, etc.? How much money they lose? When a company keeps reporting losses every quarter like this, the odds of filing for bankruptcy goes up every day, not down. The cash in hand is down to only 63% of last year same time while the short-term notes (debts) payable is up 34% to a scary $1.49 billion dollars now. It is getting worse as time passes, not better. This company does not even have enough money to cover current liabilities now. This company is a very scary bankruptcy candidate. I would not be surprised to see them file bankruptcy anytime.

    Sentiment: Strong Sell

  • Reply to

    Lets Review

    by aeishh Apr 28, 2016 10:50 AM
    careful_investor_wins careful_investor_wins May 2, 2016 2:03 PM Flag

    I don't think everyone knows there is a fairly high statistical chance of bankruptcy for this company. If everyone knows this company has high statistical chance of bankruptcy, this stock would be trading at pennies because when this company eventually files for bankruptcy, all existing shareholders would be wiped out and the stock would be worth $0. The fact that this stock is still trading so expensive shows a lot of shareholders here do not even know how to read financial reports, so this is where you can make a lot of money by short sell this stock. Where else can you find another stock with true value of NEGATIVE $63 dollars per share? This company has so heavy debts that not only the stockholders really own nothing, but also the debt holders would not get much in bankruptcy either.

    Sentiment: Strong Sell

  • Reply to

    NAV SHORT SQUEEZE by brad_welsh, Jan 15, 2016

    by telezaj May 2, 2016 6:32 PM
    careful_investor_wins careful_investor_wins May 3, 2016 2:20 AM Flag

    That was extremely bad logic. Short interest up is NOT a bullish sign. Short interest up sometimes signals the end is near. Someone in the know believes this company is about to file for bankruptcy, so they are betting on the short side heavily. And the buyback dream was even more ridiculous. This is not Apple. Apple has tons of profits and tons of extra cash, so Apple can buy back stocks. If you like stock buyback, you should sell this stock and buy AAPL or GILD. This company does not even have enough cash to pay off debts that are maturing. IT IS ON THE EDGE OF BANKRUPTCY. Hello, use your brain. A company on the edge of bankruptcy is not possible to waste money on stock buybacks. If anything, they need to sell tons of shares to get money to pay off debts to survive. LOL. $0.2 is more proper valuation for this stock since its book value is NEGATIVE $63.

    Sentiment: Strong Sell

  • Reply to

    Lets Review

    by aeishh Apr 28, 2016 10:50 AM
    careful_investor_wins careful_investor_wins May 3, 2016 2:35 AM Flag

    Don't be silly to dream of any company would buy this sales declining, money losing, heavy debt loaded company. It is not going to happen. Any company interested in buying this company can simply wait for bankruptcy to wipe out both existing stockholders and debt holders first, and then buy this company debt free at dirt cheap prices. Whatever market this company has is not worth anything when the debt level is so high. GM was the second largest auto maker in the world when it was heading for banktuprtcy, but no company in the entire world was interested in buying it at all. No company would be interested in buying this company when the numbers simply do not work out. With NEGATIVE $63 of book value due to the heavy debts. This stock is extremely expensive to trade at $14. It should trade at pennies.

    Sentiment: Strong Sell

  • The only news that lifted the stock of this company was Oppenheimer upgraded the stock and gave it a ridiculously wild high price valuation. But guess what? Oppenheimer is the investment banker of this company, and this money losing company is running low on cash, so this company needs to raise more money soon with the help of guess whom? Oppenheimer! If you believe in Oppenheimer, you are a very stupid sheep to believe in a wolf. You will be slaughtered. This is part of the reasons people hate Wall Street. It is full of dirty tricks like this. Average investors who do not know what is going on will surely lose money in stocks like this. Use your brains. The real news were the FDA panel recommended rejection of the drug. If you believe in the ridiculous lies from Oppenheimer into buying this money losing company, you will sure lose money.
    FDA will simply reject Sarepta's drug and ask Sarepta to do trials the correct way. It is silly to think FDA will approve Sarepta's drug. It is not going to happen. If FDA allows the drug to be approved without proper trials, who would still spend money to do trials the correct way? In the future, all drug companies have to do is to mobilize patients to bug FDA officials to get drug approvals. It would be a gigantic mistake to approve Sarepta's drug. It would be very stupid and a big slap on its own face if FDA is so stupid to approve Sarepta's drug. FDA should just reject, and patients can still get access to the drug by participating in the new trials. FDA officials should not change the process just because Sarepta tried to use patients to help them bypass the proper process. It would be a very bad precedence if FDA were to approve Sarepta's drug. Can you imagine all the drug companies tried to mobilize patients to bug FDA officials for all the future drug approvals? That would be horrible! Sarepta should be ashamed of tried to shortcut before and still trying to shortcut now. FDA should not encourage behaviors like Sare

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 10:20 AM Flag

    Just watch. A secondary stock offering to dilute the heck out of this stock is coming soon.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 10:24 AM Flag

    I am just asking you to use your brain. The real news is FDA panel recommended to reject the drug. And it is also facts that Oppenheimer is the investment banker of this company. Go do your own research, it is on Oppenheimer web site.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 10:28 AM Flag

    Even if the drug is approved, this company will not be worth as much as Oppenheimer claimed. The entire industry is on scrutiny for drug pricing. Especially specialty drugs like this. This company will not be able to charge much for the drug without getting scrutiny. Even GILD has to lower the drug prices recently.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 10:56 AM Flag

    The recent drug price scrutiny is changing the industry. The good days of specialty drug charging high prices is over. We are back to the days of drugs with small market will simply not make much money. No company can charge high prices for drugs anymore. The volume is more important than specialty now. This company is not worth much even if the drug is approved. Not to mention the approval is not likely at all.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 11:12 AM Flag

    Yes, it is a gift to bet on the downside. Where else would you find a stock so ridiculous that the FDA panel recommended rejection of the drug and people are still stupid to think the drug will be approved?

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 11:40 AM Flag

    What upside? Use your brain. The only real news is FDA panel recommended rejection of the drug. All analysts downgraded the stock afterward. Only Oppenheimer upgraded this stock. Why? Oppenheimer is the investment banker of this company. It lied!

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 11:49 AM Flag

    The real news is out there already. FDA panel recommended to reject the drug. How much clearer do you need? Why would you believe in the lies from the investment banker of this company, Oppenheimer, and ignore the clear rejection from FDA is beyond me.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 12:03 PM Flag

    The only failure that is important is the FDA panel recommended rejection of the drug. Everything else is just noise. Do not be stupid to believe in Oppenheimer and ignore real FDA rejections. Think about how many times FDA had slapped this company already. FDA cannot be clearer that this drug will NOT be approved.

    Sentiment: Strong Sell

  • careful_investor_wins careful_investor_wins May 3, 2016 12:28 PM Flag

    First, 10% chance of approval means 90% chance of rejection. That was why most analysts were honest to down grade the stock because the chance of approval is now slim. It is wrong to make the investors believe in the stock has hope when the reality is more likely not. And there are many diseases have no cure, it is not sufficient to approve a drug just because it has no cure. The rival drug was rejected already, and FDA knew there was no cure too. Approving a drug that was not properly tested is NOT compassion. It is the opposite.

    Sentiment: Strong Sell

DIA
173.76-6.05(-3.36%)Jun 24 6:10 PMEDT